Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 433INDUSTRY 35NIH 11NETWORK 11OTHER_GOV 4UNKNOWN 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Esophageal Neoplasms 7Breast Neoplasms 6Rectal Neoplasms 4Neoplasms 4Radiation Injuries 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Hormone Receptor Positive Advanced Breast Cancer 2Brain Neoplasms 2Varicose Veins 1Syphilis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Recurrence 1Pathologic Complete Response 1Papillomavirus Infections 1Mesothelioma, Malignant 1Lymphoid Neoplasm 1Lymphocele 1Hyperparathyroidism, Primary 1Hypercalcemia 1Head and Neck Neoplasms 1HIV Infections 1HER2-positive Breast Cancer 1Cardiovascular Diseases 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
UNKNOWN × Observational × Head and Neck Neoplasms × Clear all
NCT04740996 2022-02-07

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

ChineseAMS

Unknown
30 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡